TORONTO, Canada -- October 26, 2021 -- InvestorsHub NewsWire
-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin"
or the "Company"), a biotechnology company focused
on progressing psychedelic therapeutics, today announced that the
U.S. Food and Drug Administration ("FDA") has authorized an
Investigational New Drug ("IND") application to proceed with the
Company's sponsored feasibility study using Kernel's Flow
technology to measure ketamine's psychedelic effect on cerebral
cortex hemodynamics.
"The word psychedelic means 'mind-manifesting,' but what has
been missing is useful 'mind-imaging'—the ability to dynamically
trace the neural correlates of human conscious experience.
Conventional neuroimaging just isn't dynamic enough to study the
psychedelic experience in the brain as it happens. This study of
ketamine's psychedelic effects while wearing headgear equipped with
sensors to record brain activity could open up new frontiers of
understanding," said Dr. Alex Belser, Cybin's Chief Clinical
Officer.
Leveraging Kernel's quantitative neuroimaging technology
("Kernel Flow") may lead to new frontiers in psychedelic
therapeutics by enabling the acquisition of longitudinal brain
activity before, during and after a psychedelic experience,
providing quantification of what was previously subjective patient
reporting.
"Quantitatively measuring the brain within the context of a
psychedelic experience is a promising frontier," said Bryan
Johnson, founder and Chief Executive Officer of Kernel. "With
Kernel Flow, Cybin's researchers can start putting numbers and
quantification to subjective states of mind, including altered
ones."
Kernel Flow uses pulsed light instead of continuous wave light
to increase measured brain information. In contrast with
electroencephalography ("EEG") electrodes that usually require gel
on the head or functional magnetic resonance imaging ("fMRI")
studies that require a participant to lie in a scanner, Kernel Flow
is easily wearable. The entire system is the size and look of a
bicycle helmet and could, in the future, be more broadly used for
neuroscientific or physiological studies of brain activity during
psychedelic use.
As part of Cybin's sponsorship of the feasibility study, the
Company will retain an exclusive interest in any innovations that
are discovered or developed through its independent analysis of the
study findings. Kernel will hold the same rights relating to its
Kernel technology.
"We hope this feasibility study can bridge the gap of real-time
quantitative data collection during psychedelic treatments to
further understand the correlation of effects from these powerful
molecules. The ability to access real-time brain activity data
during a psychedelic experience has tremendous potential for the
development of future psychedelic therapeutics," stated Doug
Drysdale, Chief Executive Officer of Cybin.
About Cybin
Cybin is a leading biotechnology company focused on progressing
psychedelic therapeutics by utilizing proprietary drug discovery
platforms, innovative drug delivery systems, novel formulation
approaches and treatment regimens for psychiatric disorders.
Cautionary Notes and Forward-Looking
Statements
Certain statements in this press release constitute
forward-looking information. All statements other than statements
of historical fact contained in this press release, including,
without limitation, statements regarding Cybin's future, strategy,
plans, objectives, goals and targets, and any statements preceded
by, followed by or that include the words "believe", "expect",
"aim", "intend", "plan", "continue", "will", "may", "would",
"anticipate", "estimate", "forecast", "predict", "project", "seek",
"should" or similar expressions or the negative thereof, are
forward-looking statements. Forward-looking statements in this news
release include statements regarding the Company's proprietary drug
discovery platforms, innovative drug delivery systems, novel
formulation approaches and treatment regimens to potentially treat
psychiatric disorders.
These forward-looking statements are based on reasonable
assumptions and estimates of management of the Company at the time
such statements were made. Actual future results may differ
materially as forward-looking statements involve known and unknown
risks, uncertainties, and other factors which may cause the actual
results, performance, or achievements of the Company to materially
differ from any future results, performance, or achievements
expressed or implied by such forward-looking statements. Such
factors, among other things, include: implications of the COVID-19
pandemic on the Company's operations; fluctuations in general
macroeconomic conditions; fluctuations in securities markets;
expectations regarding the size of the psychedelics market; the
ability of the Company to successfully achieve its business
objectives; plans for growth; political, social and environmental
uncertainties; employee relations; the presence of laws and
regulations that may impose restrictions in the markets where the
Company operates; and the risk factors set out in the Company's
management's discussion and analysis for the period ended June 30,
2021 and the Company's listing statement dated November 9, 2020,
which are available under the Company's profile on www.sedar.com and with the U.S. Securities and
Exchange Commission on EDGAR at www.sec.gov. Although the
forward-looking statements contained in this news release are based
upon what management of the Company believes, or believed at the
time, to be reasonable assumptions, the Company cannot assure
shareholders that actual results will be consistent with such
forward-looking statements, as there may be other factors that
cause results not to be as anticipated, estimated or intended.
Readers should not place undue reliance on the forward-looking
statements and information contained in this news release. The
Company assumes no obligation to update the forward-looking
statements of beliefs, opinions, projections, or other factors,
should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about
Cybin's proposed products. The U.S. Food and Drug Administration,
Health Canada or other similar regulatory authorities have not
evaluated claims regarding psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds or
nutraceutical products. The efficacy of such products has not been
confirmed by approved research. There is no assurance that the use
of psilocybin, psychedelic tryptamine, tryptamine derivatives or
other psychedelic compounds or nutraceuticals can diagnose, treat,
cure or prevent any disease or condition. Vigorous scientific
research and clinical trials are needed. Cybin has not conducted
clinical trials for the use of its proposed products. Any
references to quality, consistency, efficacy and safety of
potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on Cybin's
performance and operations.
Neither the Neo Exchange Inc. nor the NYSE American LLC
stock exchange have approved or disapproved the contents of this
news release and are not responsible for the adequacy and accuracy
of the contents herein.
Contacts
Investor Contacts:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com
Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com
Media Contact:
John Kanakis
Cybin Inc.
john@cybin.com
Cybin (NEO:CYBN)
Historical Stock Chart
From May 2024 to Jun 2024
Cybin (NEO:CYBN)
Historical Stock Chart
From Jun 2023 to Jun 2024